Tonix Pharmaceuticals (NASDAQ:TNXP) released its quarterly earnings data on Tuesday. The company reported ($2.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($1.37), MarketWatch Earnings reports.
Shares of TNXP stock opened at $0.99 on Wednesday. The company has a market capitalization of $41.99 million, a PE ratio of -0.01 and a beta of 1.12. The firm has a fifty day simple moving average of $0.77 and a 200-day simple moving average of $1.03. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 0.01. Tonix Pharmaceuticals has a twelve month low of $0.39 and a twelve month high of $31.40.
Separately, ValuEngine downgraded shares of Tonix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, March 9th.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.
Featured Story: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.